{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:10:13Z","timestamp":1790838613742,"version":"4.1.0"},"reference-count":176,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014055","name":"United States Army Medical Research Acquisition Activity","doi-asserted-by":"publisher","award":["W81XWH-18-1-0789"],"award-info":[{"award-number":["W81XWH-18-1-0789"]}],"id":[{"id":"10.13039\/100014055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Over the last 25 years, inhibition of Janus kinases (JAKs) has been pursued as a modality for treating various immune and inflammatory disorders. While the clinical development of JAK inhibitors (jakinibs) began with the investigation of their use in allogeneic transplantation, their widest successful application came in autoimmune and allergic diseases. Multiple molecules have now been approved for diseases ranging from rheumatoid and juvenile arthritis to ulcerative colitis, atopic dermatitis, graft-versus-host-disease (GVHD) and other inflammatory pathologies in 80 countries around the world. Moreover, two jakinibs have also shown surprising efficacy in the treatment of hospitalized coronavirus disease-19 (COVID-19) patients, indicating additional roles for jakinibs in infectious diseases, cytokine storms and other hyperinflammatory syndromes. Jakinibs, as a class of pharmaceutics, continue to expand in clinical applications and with the development of more selective JAK-targeting and organ-selective delivery. Importantly, jakinib safety and pharmacokinetics have been investigated alongside clinical development, further cementing the potential benefits and limits of jakinib use. This review covers jakinibs that are approved or are under late phase investigation, focusing on clinical applications, pharmacokinetic and safety profiles, and future opportunities and challenges.<\/jats:p>","DOI":"10.3390\/ph15010048","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T23:29:07Z","timestamp":1640906947000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies"],"prefix":"10.3390","volume":"15","author":[{"given":"Madison","family":"Alexander","sequence":"first","affiliation":[{"name":"Translational Immunology Section, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, 10 Center Drive, Building 10 Room 10C211, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Luo","sequence":"additional","affiliation":[{"name":"Vasculitis Translational Research Program, Systemic Autoimmunity Branch, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Raimondi","sequence":"additional","affiliation":[{"name":"Vascularized Composite Allotransplantation Laboratory, Department of Plastic and Reconstructive Surgery, Johns Hopkins School of Medicine, 720 Rutland Ave., Ross Research Building, Suite 755A, Baltimore, MD 21205, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"Molecular Immunology and Inflammation Branch, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, 10 Center Drive, Building 10 Room 13C103C, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-6736","authenticated-orcid":false,"given":"Massimo","family":"Gadina","sequence":"additional","affiliation":[{"name":"Translational Immunology Section, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, 10 Center Drive, Building 10 Room 10C211, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to Jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"J. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e12811","DOI":"10.1111\/dth.12811","article-title":"Anti-interleukin 12\/23 in the treatment of erythema nodosum and Crohn disease: A case report","volume":"32","author":"Spagnuolo","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","article-title":"Managing rheumatic and musculoskeletal diseases\u2014Past, present and future","volume":"13","author":"Burmester","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: Past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: From basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT Signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13992","DOI":"10.1038\/ncomms13992","article-title":"Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection","volume":"7","author":"Eletto","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.immuni.2020.07.006","article-title":"Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function","volume":"53","author":"Gruber","year":"2020","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/art.40216","article-title":"Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci","volume":"69","author":"McIntosh","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_13","first-page":"3108","article-title":"Loss of JAK1 Drives Innate Immune Deficiency","volume":"9","author":"Klein","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J. Exp. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1007\/s11033-010-0601-5","article-title":"Meta-analysis of TYK2 gene polymorphisms association with susceptibility to autoimmune and inflammatory diseases","volume":"38","author":"Tao","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.stem.2017.08.011","article-title":"Jak1 Integrates Cytokine Sensing to Regulate Hematopoietic Stem Cell Function and Stress Hematopoiesis","volume":"21","author":"Kleppe","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.1402565","article-title":"Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis","volume":"195","author":"Hainzl","year":"2015","journal-title":"J. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.2741\/3908","article-title":"Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity","volume":"16","author":"Strobl","year":"2011","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/intimm\/dxr057","article-title":"Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice","volume":"23","author":"Ishizaki","year":"2011","journal-title":"Int. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.4049\/jimmunol.0902740","article-title":"Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis","volume":"183","author":"Oyamada","year":"2009","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"ref_23","unstructured":"(2021, August 30). Xeljanz\u00ae (Tofacitinib Citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis. Available online: https:\/\/investors.pfizer.com\/investor-news\/press-release-details\/2021\/XELJANZ-tofacitinib-citrate-Receives-Marketing-Authorization-in-the-European-Union-for-the-Treatment-of-Active-Polyarticular-Juvenile-Idiopathic-Arthritis-and-Juvenile-Psoriatic-Arthritis\/default.aspx."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","unstructured":"(2021, April 27). Baricitinib EUA Letter of Authorization, Available online: https:\/\/www.fda.gov\/media\/143822\/download."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","unstructured":"(2021, August 27). European Commission Approves RINVOQ (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis. Available online: https:\/\/news.abbvie.com\/news\/press-releases\/european-commission-approves-rinvoq-upadacitinib-as-first-jak-inhibitor-in-european-union-for-treatment-both-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis.htm."},{"key":"ref_29","unstructured":"(2021, December 09). Jyseleca: Filgotinib. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca."},{"key":"ref_30","unstructured":"(2021, December 09). UK\u2019s MHRA Grants Marketing Authorisation for Pfizer\u2019s Cibinqo\u00ae (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/uks-mhra-grants-marketing-authorisation-pfizers-cibinqor."},{"key":"ref_31","unstructured":"(2021, December 09). FDA Approves Fedratinib For Myelofibrosis, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fedratinib-myelofibrosis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"631443","DOI":"10.3389\/fvets.2021.631443","article-title":"The Association between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study","volume":"8","author":"Rynhoud","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1182\/bloodadvances.2020002097","article-title":"The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"4","author":"Zeiser","year":"2020","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Marconi, V.C., Moser, C., Gavegnano, C., Deeks, S.G., Lederman, M.M., Overton, E.T., Tsibris, A., Hunt, P.W., Kantor, A., and Sekaly, R.P. (2021). Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciab212"},{"key":"ref_38","unstructured":"(2021, November 15). Concert Pharmaceuticals Initiates THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata. Available online: https:\/\/ir.concertpharma.com\/news-releases\/news-release-details\/concert-pharmaceuticals-initiates-thrive-aa2-phase-3-clinical."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/TP.0000000000000872","article-title":"An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed","volume":"100","author":"Webber","year":"2016","journal-title":"Transplantation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"675542","DOI":"10.3389\/fimmu.2021.675542","article-title":"Tofacitinib Ameliorates Lupus through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Guimar\u00e3es, P.O., Quirk, D., Furtado, R.H., Maia, L.N., Saraiva, J.F., Antunes, M.O., Kalil Filho, R., Junior, V.M., Soeiro, A.M., and Tognon, A.P. (2021). Tofacitinib in Patients Hospitalized with COVID-19 Pneumonia. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2101643"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/1074-7613(94)90086-8","article-title":"The ups and downs of T cell costimulation","volume":"1","author":"Jenkins","year":"1994","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2013.183","article-title":"Targeting co-stimulatory pathways: Transplantation and autoimmunity","volume":"10","author":"Ford","year":"2014","journal-title":"Nat. Rev. Nephrol"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nri3215","article-title":"The impact of infection and tissue damage in solid-organ transplantation","volume":"12","author":"Chong","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrneph.2016.41","article-title":"Role of TLRs and DAMPs in allograft inflammation and transplant outcomes","volume":"12","author":"Braza","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1172\/JCI90594","article-title":"Danger signals in regulating the immune response to solid organ transplantation","volume":"127","author":"Todd","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.16456","article-title":"A short course of tofacitinib sustains the immunoregulatory effect of CTLA4-Ig in the presence of inflammatory cytokines and promotes long-term survival of murine cardiac allografts","volume":"21","author":"Iglesias","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2002791","DOI":"10.1002\/smll.202002791","article-title":"Multiphase Assembly of Small Molecule Microcrystalline Peptide Hydrogel Allows Immunomodulatory Combination Therapy for Long-Term Heart Transplant Survival","volume":"16","author":"Majumder","year":"2020","journal-title":"Small"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0000000000002204","article-title":"Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection","volume":"102","author":"Rovira","year":"2018","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jcph.1874","article-title":"Baricitinib: From Rheumatoid Arthritis to COVID-19","volume":"61","author":"Assadiasl","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","article-title":"Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","unstructured":"(2021, April 21). FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19."},{"key":"ref_56","unstructured":"(2021, April 27). NIH Closes Enrollment in Trial Comparing COVID-19 Treatment Regimens, Available online: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-closes-enrollment-trial-comparing-covid-19-treatment-regimens."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","article-title":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis","volume":"54","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_58","unstructured":"(2021, April 27). Lilly and Incyte Announce Results from the Phase 3 COV-BARRIER Study of Baricitinib in Hospitalized COVID-19 Patients. Available online: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-and-incyte-announce-results-phase-3-cov-barrier-study."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40744-019-00167-6","article-title":"Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study","volume":"6","author":"Genovese","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Abe, M., Iizuka, H., Nemoto-Hasebe, I., Nemoto, O., Toyama, H., Ohashi-Doi, K., and Kabashima, K. (2021). Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function. J. Cutan. Immunol. Allergy, 1\u20139.","DOI":"10.1002\/cia2.12213"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: Data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"235-e52","DOI":"10.1111\/vde.12218","article-title":"Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: Results of a small prospective pilot study of client-owned cats","volume":"26","author":"Ortalda","year":"2015","journal-title":"Vet. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1638\/2016-0239.1","article-title":"Treatment Success in Three Andean Bears (Tremarctos Ornatus) with Alopecia Syndrome Using Oclacitinib Maleate (Apoquel(R))","volume":"48","author":"Drake","year":"2017","journal-title":"J. Zoo Wildl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Parmentier, J.M., Voss, J., Graff, C., Schwartz, A., Argiriadi, M., Friedman, M., Camp, H.S., Padley, R.J., George, J.S., and Hyland, D. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol., 2.","DOI":"10.1186\/s41927-018-0031-x"},{"key":"ref_69","unstructured":"Cai, F., Sornasse, T., Hong, F., Camp, H., Kato, K., and McInnes, I. (2021, January 5\u20139). Biomarker driven dissection of inflammation modulatory effect of upadacitinib versus abatacept in patients with active rheumatoid arthritis refractory to biologic DMARDs. Proceedings of the ACR Convergence, Virtual. Abstract 1240."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bergman, M., Buch, M.H., Tanaka, Y., Ditera, G., Bahlas, S., Wong, E., Song, Y., Tundia, N., Suboticki, J., and Strand, V. (2021, January 5\u20139). Routine assessment of patient index data 3 (RAPID3) in patients with rheumatoid arthritis treated with long-term upadacitinib therapy. Proceedings of the ACR Convergence, Virtual. Abstract POS0670.","DOI":"10.1136\/annrheumdis-2021-eular.2090"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Fleischmann, R., Mysler, E., Bessette, L., Peterfy, C., Durez, P., Tanaka, Y., Swierkot, J., Khan, N., Bu, X., and Li, Y. (2021, January 5\u20139). Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: Results at 3 years from the SELECT-COMPARE study. Proceedings of the ACR Convergence, Virtual. Abstract 0828.","DOI":"10.1136\/rmdopen-2021-002012"},{"key":"ref_72","unstructured":"(2021, December 15). RINVOQ\u00ae (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis. Available online: https:\/\/news.abbvie.com\/news\/press-releases\/rinvoq-upadacitinib-receives-us-fda-approval-for-active-psoriatic-arthritis.htm."},{"key":"ref_73","unstructured":"Nash, P., Richette, P., Gossec, L., Marchesoni, A., Kato, K., Blondell, E., Lesser, E., McCaskill, R.M., Feng, D., and Anderson, J.K. (2020, January 5\u20139). Upadacitinib as monotherapy and in combination with non-biologic DMARDs for the treatment of psoriatic arthritis: Subgroup analysis from two phase 3 trials. Proceedings of the ACR Convergence, Virtual. Abstract 1345."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_76","unstructured":"Mease, P.J., Lertratanakul, A., Strober, B., Tsuji, S., Richetee, P., Lovan, C., Feng, D., Anderson, J., and Van den Bosch, F. (2021, January 5\u20139). Efficacy of upadacitinib in patients with psoriatic arthritis stratified by number of prior biologic disease-modifying anti-rheumatic drugs. Proceedings of the ACR Convergence, Virtual. Abstract 1356."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Merola, J.F., Richette, P., Lubrano, E., Drescher, E., Soto, L., Lovan, C., Kato, K., Lippe, R., Lane., M., and Kishimoto, M. (2021, January 2\u20135). Efficacy of upadacitinib in patients with psoriatic arthritis stratified by baseline skin severity: A subgroup analysis of two phase III trials. Proceedings of the 2021 EULAR, Virtual. Abstract POS1030.","DOI":"10.1136\/annrheumdis-2021-eular.536"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Deodhar, A., Baraliakos, X., Mcinnes, I., De Vlam, K., Bessette, L., Maniccia, A., Lippe, R., Saffore, C., Gao, T., and Song, I.H. (2021, January 2\u20135). Effect of upadacitinib on reducing pain in patients with active ankylosing spondylitis and inadequate response to nonsteroidal anti-inflammatory drugs. Proceedings of the 2021 the EULAR, Virtual. Abstract POS0907.","DOI":"10.1136\/annrheumdis-2021-eular.604"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: A randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"McInnes, I.B., Szekanecz, Z., McGonagle, D., Maksymowych, W.P., Pfeil, A., Lippe, R., Song, I.H., Lertratanakul, A., Sornasse, T., and Biljan, A. (2021). A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology, keab740.","DOI":"10.1093\/rheumatology\/keab740"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Baraliakos","year":"2018","journal-title":"Lancet"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"9636897211033778","DOI":"10.1177\/09636897211033778","article-title":"Preventive and Therapeutic Effects of a Novel JAK Inhibitor SHR0302 in Acute Graft-Versus-Host Disease","volume":"30","author":"Sun","year":"2021","journal-title":"Cell Transplant."},{"key":"ref_85","unstructured":"(2021, August 30). Reistone Announces Positive Topline Phase 2 Results for SHR0302, a Selective JAK1 Inhibitor, for Treatment of Patients with Alopecia Areata. Available online: http:\/\/www.reistonebio.com\/view\/id\/124.html."},{"key":"ref_86","unstructured":"(2021, August 30). Reistone Announces Positive Results from a Phase II Study Evaluating SHR0302 Ointment for Patients with Mild-to-Moderate Atopic Dermatitis. Available online: http:\/\/www.reistonebio.com\/view\/id\/126.html."},{"key":"ref_87","unstructured":"(2021, August 30). Reistone Announces First Patient Dosed in Phase III Global Study in Atopic Dermatitis. Available online: http:\/\/www.reistonebio.com\/view\/id\/116.html."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_89","unstructured":"(2021, May 04). Bristol Myers Squibb Announces Deucravacitinib (BMS-986165) Demonstrated Superiority to Placebo and Otezla (Apremilast) in Pivotal Phase 3 Psoriasis Study. Available online: https:\/\/news.bms.com\/news\/corporate-financial\/2020\/Bristol-Myers-Squibb-Announces-Deucravacitinib-BMS-986165-Demonstrated-Superiority-to-Placebo-and-Otezla-apremilast-in-Pivotal-Phase-3-Psoriasis-Study\/default.aspx."},{"key":"ref_90","unstructured":"(2021, May 04). Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla (Apremilast). Available online: https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Second-Pivotal-Phase-3-Psoriasis-Study-Showing-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast\/default.aspx."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Mease, P.J., Deodhar, A., Van den Heijde, D., Behrens, F., Kivitz, A., Lehman, T., Wei, L., Nys, M., Banerjee, S., and Nowark, M. (2021, January 2\u20135). Efficacy of Deucravacitinib, An Oral, Selective Tyrosine Kinase 2 Inhibitor, In Musculoskeletal Manifestations Of Active Psoriatic Arthritis In A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial. Proceedings of the 2021 EULAR, Virtual. Abstract OP0227.","DOI":"10.1136\/annrheumdis-2021-eular.2653"},{"key":"ref_92","unstructured":"(2021, August 30). Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis. Available online: https:\/\/news.bms.com\/news\/details\/2020\/Bristol-Myers-Squibb-Presents-Late-Breaking-Phase-2-Data-Demonstrating-the-Safety-and-Efficacy-of-Deucravacitinib-BMS-986165-in-Patients-with-Psoriatic-Arthritis\/default.aspx."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J. Pharmacol. Exp Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2019-124231","article-title":"Rapid and Durable Responses with the SYK\/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed\/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2019-123986","article-title":"A Phase 2 Study of the Dual SYK\/JAK Inhibitor Cedulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed\/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/2040620715586527","article-title":"Clinical potential of pacritinib in the treatment of myelofibrosis","volume":"6","author":"Mead","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/leu.2011.148","article-title":"SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies","volume":"25","author":"Hart","year":"2011","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_101","unstructured":"(2021, August 30). Pfizer Announces Positive Top-Line Results from Phase 2b\/3 Trial of Ritlecitinib in Alopecia Areata. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-results-phase-2b3-trial."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_103","unstructured":"Theravance Biopharma, Inc (2021, July 15). Reports Third Quarter 2020 Financial Results and Provides Business Update. Available online: https:\/\/investor.theravance.com\/news-releases\/news-release-details\/theravance-biopharma-inc-reports-third-quarter-2020-financial."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2100673","DOI":"10.1183\/13993003.00673-2021","article-title":"A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19","volume":"58","author":"Singh","year":"2021","journal-title":"Eur. Respir J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/j.1600-6143.2008.02307.x","article-title":"Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics","volume":"8","author":"Weimar","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1097\/TXD.0000000000000819","article-title":"Efficacy and Safety of a Tofacitinib-based Immunosuppressive Regimen After Kidney Transplantation: Results From a Long-term Extension Trial","volume":"4","author":"Busque","year":"2018","journal-title":"Transplant. Direct"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2021-eular.1416","article-title":"Infections and serious infections in the filgotinib rheumatoid arthritis program","volume":"80","author":"Galloway","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_110","first-page":"9004","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme","volume":"21","author":"Cohen","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00393-020-00796-1","article-title":"Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs","volume":"80","author":"Lee","year":"2021","journal-title":"Z. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.113.209304","article-title":"Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis","volume":"348","author":"Dowty","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/art.24567","article-title":"The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo","volume":"60","author":"Kremer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Strand","year":"2017","journal-title":"Rheumatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e001370","DOI":"10.1136\/rmdopen-2020-001370","article-title":"Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib","volume":"6","author":"Kay","year":"2020","journal-title":"RMD Open"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar4673","article-title":"Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: Results from clinical trials","volume":"16","author":"Isaacs","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-020-00931-6","article-title":"JAK Inhibitors: What Is New?","volume":"22","author":"Reddy","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief Report: Risk of Gastrointestinal Perforation among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_128","unstructured":"FitzGerald, O., Gladman, D., Mease, P., Ritchlin, C., Smolen, J., Gao, L., Hu, S., Nowak, M., Banerjee, S., and Catless, I. (2021, January 5\u20139). Biomarker changes with selective tyrosine kinase 2 inhibitor, deucravacitinib, in PsA: Effects on disease markers and tyrosine kinase 2- versus janus kinase 1\/2\/3-mediated pathways. Proceedings of the ACR Convergence, Virtual. Abstract 0490."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eabe4724","DOI":"10.1126\/sciadv.abe4724","article-title":"JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality","volume":"7","author":"Stebbing","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"(2021). Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: An observational cohort study. Rheumatology, 60, 399\u2013407.","DOI":"10.1093\/rheumatology\/keaa587"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ibd\/izaa227","article-title":"Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management","volume":"27","author":"Sands","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J. Clin. Lipidol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","article-title":"Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: A meta-analysis of randomized controlled trials","volume":"18","author":"Qiu","year":"2019","journal-title":"Lipids Health Dis."},{"key":"ref_136","unstructured":"(2021, May 04). FDA Approves Boxed Warning about Increased Risk of Blood Clots and Death with Higher Dose of Arthritis and Ulcerative Colitis Medicine Tofacitinib (Xeljanz, Xeljanz XR), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."},{"key":"ref_137","unstructured":"(2021, September 21). FDA Requires Warnings about Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"ref_138","unstructured":"(2021, September 24). Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of Xeljanz\u00ae (tofacitinib) in Subjects with Rheumatoid Arthritis (RA). Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.mayocp.2020.12.035","article-title":"Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis","volume":"96","author":"Bilal","year":"2021","journal-title":"Mayo Clin. Proc"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_143","unstructured":"Khorrow-Khavar, F., Kim, S., Lee, H., Been Lee, S., and and Desai, R. (2021, January 5\u20139). Risk of cardiovascular outcomes in patients treated with tofacitinib: First results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Proceedings of the ACR Convergence, Virtual. Abstract 1939."},{"key":"ref_144","unstructured":"Charles-Schoeman, C., Buch, M., Dougados, M., Bhatt, D.L., Giles, J., Vranic, I., Wu, J., Wang, C., Menon, S., and Rivas, J.L. (2021, January 5\u20139). Risk factors for major adverse cardiovascular events in patients aged \u2265 50 years with RA and \u22651 additional cardiovascular risk factor: Results from a phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors. Proceedings of the ACR Convergence, Virtual. Abstract 0958."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Taylor, P.C., Takeuchi, T., Burmester, G.R., Durez, P., Smolen, J.S., Deberdt, W., Issa, M., Terres, J.R., Bello, N., and Winthrop, K.L. (2021). Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: Final results from long-term extension study and integrated database. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e00537","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Tam","year":"2015","journal-title":"Future Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jcph.178","article-title":"Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease","volume":"54","author":"Krishnaswami","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/cpdd.868","article-title":"Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study","volume":"9","author":"Zhao","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-017-0605-6","article-title":"Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials","volume":"57","author":"Klunder","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and Pharmacokinetic\/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin. Pharmacokinet"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.30","article-title":"Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: A case study with ruxolitinib","volume":"97","author":"Shi","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpdd.77","article-title":"Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients","volume":"3","author":"Chen","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"S725","DOI":"10.1093\/ecco-jcc\/jjaa014","article-title":"Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease","volume":"14","author":"Lefevre","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","article-title":"Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib","volume":"10","author":"Posada","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_163","unstructured":"(2021, August 20). FDA Olumiant Label, Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bcp.13726","article-title":"Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor","volume":"84","author":"Namour","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Muensterman, E., Engelhardt, B., Gopalakrishnan, S., Anderson, J., and Mohamed, M.E. (2021, January 5\u20139). Upadacitinib pharmacokinetics and ex-posure-response relationships for efficacy and safety in psoriatic arthritis\u2014Analysis of the phase 3 SELECT-PsA studies. Proceedings of the ACR Convergence, Virtual. Abstract POS1054.","DOI":"10.1136\/annrheumdis-2021-eular.2182"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e000491","DOI":"10.1136\/rmdopen-2017-000491","article-title":"Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: An analysis of pooled data from open-label long-term extension studies","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: The ANSWER cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"keab246.009","DOI":"10.1093\/rheumatology\/keab246.009","article-title":"O10 Characteristics of patients who discontinued baricitinib treatment within 12 months and reasons for discontinuation: Real-world data","volume":"60","author":"Lwin","year":"2021","journal-title":"Rheumatology"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Alunno, A., Najm, A., Machado, P.M., Bertheussen, H., Burmester, G.R., Carubbi, F., De Marco, G., Giacomelli, R., Hermine, O., and Isaacs, J.D. (2021). 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann. Rheum. Dis.","DOI":"10.1136\/annrheumdis-2021-221366"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1016\/S2665-9913(21)00314-3","article-title":"Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry","volume":"4","author":"Seror","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41423-020-00526-2","article-title":"New insights into the cell- and tissue-specificity of glucocorticoid actions","volume":"18","author":"Quatrini","year":"2021","journal-title":"Cell Mol Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nurpra.2019.03.024","article-title":"Physiologic Steroid Tapering","volume":"15","author":"Siegel","year":"2019","journal-title":"J. Nurse Pract."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Abebe, R., Hatiya, H., Abera, M., Megersa, B., and Asmare, K. (2016). Bovine mastitis: Prevalence, risk factors and isolation of Staphylococcus aureus in dairy herds at Hawassa milk shed, South Ethiopia. BMC Vet. Res., 12.","DOI":"10.1186\/s12917-016-0905-3"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Citera, G., Jain, R., Irazoque-Palazuelos, F., Guzman, R., Madariaga, H., Gruben, D.C., Wang, L., Stockert, L., Hsu, M.A., and San-tana, K. (2020, January 3\u20136). Tofacitinib in patients with rheumatoid arthritis and indicative of depression and\/or anxiety: A post hoc analysis of phase 3 and phase 3B\/4 clinical trials. Proceedings of the 2020 EULAR, Virtual. Abstract THU0196.","DOI":"10.1136\/annrheumdis-2020-eular.417"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e025333","DOI":"10.1136\/bmjopen-2018-025333","article-title":"Protocol for the insight study: A randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation","volume":"8","author":"Khandaker","year":"2018","journal-title":"BMJ Open"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:55:56Z","timestamp":1760169356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/1\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["ph15010048"],"URL":"https:\/\/doi.org\/10.3390\/ph15010048","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]}}}